NCBI PubMed National Library of Medicine

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Books

Search PubMed for "Tack BF"[au] Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Sort Save Text Clip Add Order

Show: 50 Items 1-50 of 81 Page 1 of 2 Select page: 1 2

Entrez PubMed

PubMed Services

Related Resources

1: Steinstraesser L, Tack BF, Waring AJ, Hong T, Boo LM, Fan MH, Remick DI, Su GL, Lehrer RI, Wang SC. Related Articles

Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns.

Antimicrob Agents Chemother. 2002 Jun;46(6):1837-44.
PMID: 12019098 [PubMed - in process]

2: Sawai MV, Waring AJ, Kearney WR, McCray PB Jr, Forsyth WR, Lehrer RI, Tack BF. Related Articles

Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides.

Protein Eng. 2002 Mar;15(3):225-32.
PMID: 11932493 [PubMed - in process]

3: Tack BF, Sawai MV, Kearney WR, Robertson AD, Sherman MA, Wang W, Hong T, Boo LM, Wu H, Waring AJ, Lehrer RI. Related Articles, Protein, Structure

SMAP-29 has two LPS-binding sites and a central hinge.

Eur J Biochem. 2002 Feb;269(4):1181-9.
PMID: 11856344 [PubMed - indexed for MEDLINE]

4: Zarember KA, Katz SS, Tack BF, Doukhan L, Weiss J, Elsbach P. Related Articles

Host defense functions of proteolytically processed and parent (unprocessed) cathelicidins of rabbit granulocytes.

Infect Immun. 2002 Feb;70(2):569-76.
PMID: 11796584 [PubMed - indexed for MEDLINE]

5: Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB Jr, Tack BF, Vogel HJ. Related Articles, Nucleotide, Protein, Structure

The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus.

J Biol Chem. 2002 Mar 8;277(10):8279-89.
PMID: 11741980 [PubMed - indexed for MEDLINE]

6: Kalfa VC, Jia HP, Kunkle RA, McCray PB Jr, Tack BF, Brogden KA. Related Articles

Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells.

Antimicrob Agents Chemother. 2001 Nov;45(11):3256-61.
PMID: 11600395 [PubMed - indexed for MEDLINE]

☐ **7:** Guthmiller JM, Vargas KG, Srikantha R, Schomberg LL, Weistroffer PL, McCray PB Jr, Tack BF. Related Articles

Susceptibilities of oral bacteria and yeast to mammalian cathelicidins.
Antimicrob Agents Chemother. 2001 Nov;45(11):3216-9.
PMID: 11600383 [PubMed - indexed for MEDLINE]

☐ **8:** Yamaguchi S, Huster D, Waring A, Lehrer RI, Kearney W, Tack BF, Hong M. Related Articles

Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy.
Biophys J. 2001 Oct;81(4):2203-14.
PMID: 11566791 [PubMed - indexed for MEDLINE]

☐ **9:** Saiman L, Tabibi S, Starner TD, San Gabriel P, Winokur PL, Jia HP, McCray PB Jr, Tack BF. Related Articles

Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.
Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44.
PMID: 11557478 [PubMed - indexed for MEDLINE]

☐ **10:** Carothers DG, Graham SM, Jia HP, Ackermann MR, Tack BF, McCray PB Jr. Related Articles

Production of beta-defensin antimicrobial peptides by maxillary sinus mucosa.
Am J Rhinol. 2001 May-Jun;15(3):175-9.
PMID: 11453504 [PubMed - indexed for MEDLINE]

☐ **11:** Sawai MV, Jia HP, Liu L, Aseyev V, Wiencek JM, McCray PB Jr, Ganz T, Kearney WR, Tack BF. Related Articles, Protein, Structure

The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment.
Biochemistry. 2001 Apr 3;40(13):3810-6.
PMID: 11300761 [PubMed - indexed for MEDLINE]

☐ **12:** Jia HP, Schutte BC, Schudy A, Linzmeier R, Guthmiller JM, Johnson GK, Tack BF, Mitros JP, Rosenthal A, Ganz T, McCray PB Jr. Related Articles, Nucleotide, OMIM, Protein

Discovery of new human beta-defensins using a genomics-based approach.
Gene. 2001 Jan 24;263(1-2):211-8.
PMID: 11223260 [PubMed - indexed for MEDLINE]

☐ **13:** Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, Wetsel RA. Related Articles

Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma.
J Immunol. 2001 Feb 1;166(3):2025-32.
PMID: 11160252 [PubMed - indexed for MEDLINE]

☐ **14:** Jia HP, Starner T, Ackermann M, Kirby P, Tack BF, McCray PB Jr. Related Articles, OMIM

Abundant human beta-defensin-1 expression in milk and mammary gland epithelium.
J Pediatr. 2001 Jan;138(1):109-12.
PMID: 11148522 [PubMed - indexed for MEDLINE]

☐ **15:** Brogden KA, Kalfa VC, Ackermann MR, Palmquist DE, McCray PB Jr, Tack BF. Related Articles

The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection.

Antimicrob Agents Chemother. 2001 Jan;45(1):331-4.
PMID: 11120991 [PubMed - indexed for MEDLINE]

☐ **16:** Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Related Articles

Synergistic and additive killing by antimicrobial factors found in human airway surface liquid.
Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L799-805.
PMID: 11053013 [PubMed - indexed for MEDLINE]

☐ **17:** Hang JQ, Tack BF, Feiss M. Related Articles

ATPase center of bacteriophage lambda terminase involved in post-cleavage stages of DNA packaging: identification of ATP-interactive amino acids.
J Mol Biol. 2000 Sep 29;302(4):777-95.
PMID: 10993723 [PubMed - indexed for MEDLINE]

☐ **18:** Jia HP, Wowk SA, Schutte BC, Lee SK, Vivado A, Tack BF, Bevins CL, McCray PB Jr. Related Articles, Nucleotide, Protein

A novel murine beta -defensin expressed in tongue, esophagus, and trachea.
J Biol Chem. 2000 Oct 27;275(43):33314-20.
PMID: 10922379 [PubMed - indexed for MEDLINE]

☐ **19:** Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB Jr, Lehrer RI, Welsh MJ, Tack BF. Related Articles

Bactericidal activity of mammalian cathelicidin-derived peptides.
Infect Immun. 2000 May;68(5):2748-55.
PMID: 10768969 [PubMed - indexed for MEDLINE]

☐ **20:** Jia HP, Mills JN, Barahmand-Pour F, Nishimura D, Mallampali RK, Wang G, Wiles K, Tack BF, Bevins CL, McCray PB Jr. Related Articles, Nucleotide, Protein

Molecular cloning and characterization of rat genes encoding homologues of human beta-defensins.
Infect Immun. 1999 Sep;67(9):4827-33.
PMID: 10456937 [PubMed - indexed for MEDLINE]

☐ **21:** Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB Jr. Related Articles

Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands.
Infect Immun. 1999 Jun;67(6):2740-5.
PMID: 10338476 [PubMed - indexed for MEDLINE]

☐ **22:** Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB Jr. Related Articles, OMIM, Free in PMC

Production of beta-defensins by human airway epithelia.
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14961-6.
PMID: 9843998 [PubMed - indexed for MEDLINE]

☐ **23:** Fey MF, Moffat GJ, Vik DP, Meisenhelder J, Saris CJ, Hunter T, Tack BF. Related Articles, Nucleotide, Protein

Complete structure of the murine p36 (annexin II) gene. Identification of mRNAs for both the murine and the human gene with alternatively spliced 5' noncoding exons.
Biochim Biophys Acta. 1996 May 2;1306(2-3):160-70.

PMID: 8634333 [PubMed - indexed for MEDLINE]

☐ **24:** Moffat GJ, Tack BF. Related Articles, Nucleotide

Regulation of C4b-binding protein gene expression by the acute-phase mediators tumor necrosis factor-alpha, interleukin-6, and interleukin-1.
Biochemistry. 1992 Dec 15;31(49):12376-84.
PMID: 1339286 [PubMed - indexed for MEDLINE]

☐ **25:** Moffat GJ, Vik DP, Noack D, Tack BF. Related Articles, Nucleotide, Protein

Complete structure of the murine C4b-binding protein gene and regulation of its expression by dexamethasone.
J Biol Chem. 1992 Oct 5;267(28):20400-6.
PMID: 1400358 [PubMed - indexed for MEDLINE]

☐ **26:** Carney DF, Haviland DL, Noack D, Wetsel RA, Vik DP, Tack BF. Related Articles, Nucleotide

Structural aspects of the human C5 gene. Intron/exon organization, 5'-flanking region features, and characterization of two truncated cDNA clones.
J Biol Chem. 1991 Oct 5;266(28):18786-91.
PMID: 1917999 [PubMed - indexed for MEDLINE]

☐ **27:** Vik DP, Amiguet P, Moffat GJ, Fey M, Amiguet-Barras F, Wetsel RA, Tack BF. Related Articles, Nucleotide, Protein

Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence.
Biochemistry. 1991 Jan 29;30(4):1080-5.
PMID: 1703437 [PubMed - indexed for MEDLINE]

☐ **28:** Munoz-Canoves P, Vik DP, Tack BF. Related Articles

Mapping of a retinoic acid-responsive element in the promoter region of the complement factor H gene.
J Biol Chem. 1990 Nov 25;265(33):20065-8.
PMID: 1700780 [PubMed - indexed for MEDLINE]

☐ **29:** Vik DP, Munoz-Canoves P, Kozono H, Martin LG, Tack BF, Chaplin DD. Related Articles, Nucleotide, Protein

Identification and sequence analysis of four complement factor H-related transcripts in mouse liver.
J Biol Chem. 1990 Feb 25;265(6):3193-201.
PMID: 1689298 [PubMed - indexed for MEDLINE]

☐ **30:** Amiguet P, D'Eustachio P, Kristensen T, Wetsel RA, Saris CJ, Hunter T, Chaplin DD, Tack BF. Related Articles, Nucleotide, Protein

Structure and chromosome assignment of the murine p36 (calpactin I heavy chain) gene.
Biochemistry. 1990 Feb 6;29(5):1226-32.
PMID: 2138915 [PubMed - indexed for MEDLINE]

☐ **31:** Vik DP, Munoz-Canoves P, Chaplin DD, Tack BF. Related Articles

Factor H.
Curr Top Microbiol Immunol. 1990;153:147-62. Review.
PMID: 2137073 [PubMed - indexed for MEDLINE]

☐ **32:** Barnum SR, Fey G, Tack BF. Related Articles

Biosynthesis and genetics of C3.
Curr Top Microbiol Immunol. 1990;153:23-43. Review. No abstract available.
PMID: 2105189 [PubMed - indexed for MEDLINE]

☐ **33:** Munoz-Canoves P, Tack BF, Vik DP. Related Articles, Nucleotide, Protein
Analysis of complement factor H mRNA expression: dexamethasone and IFN-gamma increase the level of H in L cells.
Biochemistry. 1989 Dec 26;28(26):9891-7.
PMID: 2533512 [PubMed - indexed for MEDLINE]

☐ **34:** Barnum SR, Kristensen T, Chaplin DD, Seldin MF, Tack BF. Related Articles, OMIM
Molecular analysis of the murine C4b-binding protein gene. Chromosome assignment and partial gene organization.
Biochemistry. 1989 Oct 17;28(21):8312-7.
PMID: 2574991 [PubMed - indexed for MEDLINE]

☐ **35:** Barnum SR, Amiguet P, Amiguet-Barras F, Fey G, Tack BF. Related Articles
Complete intron/exon organization of DNA encoding the alpha' chain of human C3.
J Biol Chem. 1989 May 25;264(15):8471-4.
PMID: 2722781 [PubMed - indexed for MEDLINE]

☐ **36:** Kingsmore SF, Vik DP, Kurtz CB, Leroy P, Tack BF, Weis JH, Seldin MF. Related Articles
Genetic organization of complement receptor-related genes in the mouse.
J Exp Med. 1989 Apr 1;169(4):1479-84.
PMID: 2564419 [PubMed - indexed for MEDLINE]

☐ **37:** Vik DP, Keeney JB, Munoz-Canoves P, Chaplin DD, Tack BF. Related Articles, Nucleotide, Protein
Structure of the murine complement factor H gene.
J Biol Chem. 1988 Nov 15;263(32):16720-4.
PMID: 2972715 [PubMed - indexed for MEDLINE]

☐ **38:** Wetsel RA, Lemons RS, Le Beau MM, Barnum SR, Noack D, Tack BF. Related Articles, Nucleotide, OMIM, Protein
Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9.
Biochemistry. 1988 Mar 8;27(5):1474-82.
PMID: 3365401 [PubMed - indexed for MEDLINE]

☐ **39:** Moore MD, Cooper NR, Tack BF, Nemerow GR. Related Articles, Nucleotide, OMIM, Protein
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9194-8.
PMID: 2827171 [PubMed - indexed for MEDLINE]

☐ **40:** Saris CJ, Kristensen T, D'Eustachio P, Hicks LJ, Noonan DJ, Hunter T, Tack BF. Related Articles, Nucleotide, OMIM, Protein
cDNA sequence and tissue distribution of the mRNA for bovine and murine p11, the S100-related light chain of the protein-tyrosine kinase substrate p36 (calpactin I).
J Biol Chem. 1987 Aug 5;262(22):10663-71.
PMID: 3038891 [PubMed - indexed for MEDLINE]

☐ **41:** Kristensen T, Ogata RT, Chung LP, Reid KB, Tack BF. Related Articles, Nucleotide, Protein

cDNA structure of murine C4b-binding protein, a regulatory component of the serum complement system.
Biochemistry. 1987 Jul 28;26(15):4668-74.
PMID: 3663616 [PubMed - indexed for MEDLINE]

☐ **42:** Kristensen T, D'Eustachio P, Ogata RT, Chung LP, Reid KB, Tack BF. Related Articles
The superfamily of C3b/C4b-binding proteins.
Fed Proc. 1987 May 15;46(7):2463-9. Review.
PMID: 2952524 [PubMed - indexed for MEDLINE]

☐ **43:** Wheat WH, Wetsel R, Falus A, Tack BF, Strunk RC. Related Articles
The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency.
J Exp Med. 1987 May 1;165(5):1442-7.
PMID: 3572304 [PubMed - indexed for MEDLINE]

☐ **44:** Wetsel RA, Ogata RT, Tack BF. Related Articles, Nucleotide, Protein
Primary structure of the fifth component of murine complement.
Biochemistry. 1987 Feb 10;26(3):737-43.
PMID: 2436653 [PubMed - indexed for MEDLINE]

☐ **45:** D'Eustachio P, Kristensen T, Wetsel RA, Riblet R, Taylor BA, Tack BF. Related Articles
Chromosomal location of the genes encoding complement components C5 and factor H in the mouse.
J Immunol. 1986 Dec 15;137(12):3990-5.
PMID: 2878046 [PubMed - indexed for MEDLINE]

☐ **46:** Kristensen T, Saris CJ, Hunter T, Hicks LJ, Noonan DJ, Glenney JR Jr, Tack BF. Related Articles, Nucleotide, Protein
Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: homology with the human phospholipase A2 inhibitor lipocortin.
Biochemistry. 1986 Aug 12;25(16):4497-503.
PMID: 2945590 [PubMed - indexed for MEDLINE]

☐ **47:** Saris CJ, Tack BF, Kristensen T, Glenney JR Jr, Hunter T. Related Articles, Nucleotide, Protein
The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin I heavy chain) reveals a multidomain protein with internal repeats.
Cell. 1986 Jul 18;46(2):201-12.
PMID: 3013423 [PubMed - indexed for MEDLINE]

☐ **48:** Kristensen T, Tack BF. Related Articles, Nucleotide, Protein
Murine protein H is comprised of 20 repeating units, 61 amino acids in length.
Proc Natl Acad Sci U S A. 1986 Jun;83(11):3963-7.
PMID: 2940596 [PubMed - indexed for MEDLINE]

☐ **49:** Kristensen T, Wetsel RA, Tack BF. Related Articles, Nucleotide, OMIM, Protein
Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2.
J Immunol. 1986 May 1;136(9):3407-11.
PMID: 2937845 [PubMed - indexed for MEDLINE]

☐ 50: Glenney JR Jr, Tack BF. Related Articles, Protein

Amino-terminal sequence of p36 and associated p10: identification of the site of tyrosine phosphorylation and homology with S-100.

Proc Natl Acad Sci U S A. 1985 Dec;82(23):7884-8.
PMID: 2415974 [PubMed - indexed for MEDLINE]

☐51: Sipe JD, Colten HR, Goldberger G, Edge MD, Tack BF, Cohen AS, Whitehead AS. Related Articles, Nucleotide, OMIM, Protein

Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA.
Biochemistry. 1985 Jun 4;24(12):2931-6.
PMID: 3839415 [PubMed - indexed for MEDLINE]

☐52: Lundwall AB, Wetsel RA, Kristensen T, Whitehead AS, Woods DE, Ogden RC, Colten HR, Tack BF. Related Articles, Nucleotide, Protein

Isolation and sequence analysis of a cDNA clone encoding the fifth complement component.
J Biol Chem. 1985 Feb 25;260(4):2108-12.
PMID: 2579066 [PubMed - indexed for MEDLINE]

☐53: Sottrup-Jensen L, Folkersen J, Kristensen T, Tack BF. Related Articles, OMIM

Partial primary structure of human pregnancy zone protein: extensive sequence homology with human alpha 2-macroglobulin.
Proc Natl Acad Sci U S A. 1984 Dec;81(23):7353-7.
PMID: 6209714 [PubMed - indexed for MEDLINE]

☐54: Lundwall A, Wetsel RA, Domdey H, Tack BF, Fey GH. Related Articles, Nucleotide, Protein

Structure of murine complement component C3. I. Nucleotide sequence of cloned complementary and genomic DNA coding for the beta chain.
J Biol Chem. 1984 Nov 25;259(22):13851-6.
PMID: 6548745 [PubMed - indexed for MEDLINE]

☐55: Wetsel RA, Lundwall A, Davidson F, Gibson T, Tack BF, Fey GH. Related Articles, Nucleotide, Protein

Structure of murine complement component C3. II. Nucleotide sequence of cloned complementary DNA coding for the alpha chain.
J Biol Chem. 1984 Nov 25;259(22):13857-62.
PMID: 6094532 [PubMed - indexed for MEDLINE]

☐56: Fey GH, Lundwall A, Wetsel RA, Tack BF, de Bruijn MH, Domdey H. Related Articles, Nucleotide, Protein

Nucleotide sequence of complementary DNA and derived amino acid sequence of murine complement protein C3.
Philos Trans R Soc Lond B Biol Sci. 1984 Sep 6;306(1129):333-44.
PMID: 6208565 [PubMed - indexed for MEDLINE]

☐57: Thomas ML, Davidson FF, Tack BF. Related Articles

Reduction of the beta-Cys-gamma-Glu thiol ester bond of human C3 with sodium borohydride.
J Biol Chem. 1983 Nov 25;258(22):13580-6.
PMID: 6139373 [PubMed - indexed for MEDLINE]

☐ **58:** Thomas ML, Tack BF. Related Articles, Protein
Identification and alignment of a thiol ester site in the third component of guinea pig complement.
Biochemistry. 1983 Feb 15;22(4):942-7. No abstract available.
PMID: 6838833 [PubMed - indexed for MEDLINE]

☐ **59:** Tack BF. Related Articles
The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin.
Springer Semin Immunopathol. 1983;6(4):259-82. Review. No abstract available.
PMID: 6198737 [PubMed - indexed for MEDLINE]

☐ **60:** Hall RE, Blaese RM, Davis AE 3rd, Decker JM, Tack BF, Colten HR, Muchmore AV. Related Articles
Cooperative interaction of factor B and other complement components with mononuclear cells in the antibody-independent lysis of xenogeneic erythrocytes.
J Exp Med. 1982 Sep 1;156(3):834-43.
PMID: 7108444 [PubMed - indexed for MEDLINE]

☐ **61:** Hostetter MK, Thomas ML, Rosen FS, Tack BF. Related Articles
Binding of C3b proceeds by a transesterification reaction at the thiolester site.
Nature. 1982 Jul 1;298(5869):72-5. No abstract available.
PMID: 6806664 [PubMed - indexed for MEDLINE]

☐ **62:** Thomas ML, Janatova J, Gray WR, Tack BF. Related Articles, Protein
Third component of human complement: localization of the internal thiolester bond.
Proc Natl Acad Sci U S A. 1982 Feb;79(4):1054-8. No abstract available.
PMID: 6175959 [PubMed - indexed for MEDLINE]

☐ **63:** Goldberger G, Thomas ML, Tack BF, Williams J, Colten HR, Abraham GN. Related Articles, Protein
NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component.
J Biol Chem. 1981 Dec 25;256(24):12617-9.
PMID: 6458605 [PubMed - indexed for MEDLINE]

☐ **64:** Harrison RA, Thomas ML, Tack BF. Related Articles, Protein
Sequence determination of the thiolester site of the fourth component of human complement.
Proc Natl Acad Sci U S A. 1981 Dec;78(12):7388-92.
PMID: 6950384 [PubMed - indexed for MEDLINE]

☐ **65:** Arnaout MA, Melamed J, Tack BF, Colten HR. Related Articles
Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer.
J Immunol. 1981 Oct;127(4):1348-54.
PMID: 7276561 [PubMed - indexed for MEDLINE]

☐ **66:** Janatova J, Tack BF. Related Articles

Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component.
Biochemistry. 1981 Apr 28;20(9):2394-402. No abstract available.
PMID: 7236609 [PubMed - indexed for MEDLINE]

☐ **67:** Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. Related Articles

Large scale isolation of functionally active components of the human complement system.
J Biol Chem. 1981 Apr 25;256(8):3995-4006.
PMID: 6783652 [PubMed - indexed for MEDLINE]

☐ **68:** Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW. Related Articles

Evidence for presence of an internal thiolester bond in third component of human complement.
Proc Natl Acad Sci U S A. 1980 Oct;77(10):5764-8.
PMID: 6934510 [PubMed - indexed for MEDLINE]

☐ **69:** Tack BF, Dean J, Eilat D, Lorenz PE, Schechter AN. Related Articles

Tritium labeling of proteins to high specific radioactivity by reduction methylation.
J Biol Chem. 1980 Sep 25;255(18):8842-7.
PMID: 6773951 [PubMed - indexed for MEDLINE]

☐ **70:** Janatova J, Tack BF, Prahl JW. Related Articles

Third component of human complement: structural requirements for its function.
Biochemistry. 1980 Sep 16;19(19):4479-85. No abstract available.
PMID: 7407086 [PubMed - indexed for MEDLINE]

☐ **71:** Janatova J, Lorenz PE, Schechter AN, Prahl JW, Tack BF. Related Articles

Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation.
Biochemistry. 1980 Sep 16;19(19):4471-8.
PMID: 7407085 [PubMed - indexed for MEDLINE]

☐ **72:** Tack BF, Morris SC, Prahl JW. Related Articles

Third component of human complement: structural analysis of the polypeptide chains of C3 and C3b.
Biochemistry. 1979 Apr 17;18(8):1497-503. No abstract available.
PMID: 427127 [PubMed - indexed for MEDLINE]

☐ **73:** Tack BF, Morris SC, Prahl JW. Related Articles, OMIM

Fifth component of human complement: purification from plasma and polypeptide chain structure.
Biochemistry. 1979 Apr 17;18(8):1490-7. No abstract available.
PMID: 106884 [PubMed - indexed for MEDLINE]

☐ **74:** Takahashi M, Tack BF, Nussenzweig V. Related Articles

Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.
J Exp Med. 1977 Jan 1;145(1):86-100.
PMID: 830792 [PubMed - indexed for MEDLINE]

☐ **75:** Prahl JW, Tack BF, Todd CW. Related Articles

Chemical studies of the heavy chain of rabbit IgG lacking group a allotypic markers.
Ann Immunol (Paris). 1974 Jan;125C(1-2):99-106. No abstract available.
PMID: 4142573 [PubMed - indexed for MEDLINE]

☐ **76:** Tack BF, Feintuch K, Todd CW, Prahl JW. Related Articles

Rabbit immunoglobulin lacking group a allotypic specificities. I. Isolation and nature of heavy chain.
Biochemistry. 1973 Dec 4;12(25):5172-7. No abstract available.
PMID: 4802020 [PubMed - indexed for MEDLINE]

☐ **77:** Prahl JW, Tack BF, Todd CW. Related Articles

Rabbit immunoglobulin lacking group a allotypic specificities. 3. Variable region structure and genetic control.
Biochemistry. 1973 Dec 4;12(25):5181-6. No abstract available.
PMID: 4792302 [PubMed - indexed for MEDLINE]

☐ **78:** Tack BF, Prahl JW, Todd CW. Related Articles

Rabbit immunoglobulin lacking group a allotypic specificites. II. Retention of constant region d-11 and d-12 specificities.
Biochemistry. 1973 Dec 4;12(25):5178-80. No abstract available.
PMID: 4792301 [PubMed - indexed for MEDLINE]

☐ **79:** Kindt TJ, Seide RK, Tack BF, Todd CW. Related Articles

Diverse expression of group a allotype specificities on the heavy chains of homogeneous rabbit antibodies.
J Exp Med. 1973 Jul 1;138(1):33-43. No abstract available.
PMID: 4123829 [PubMed - indexed for MEDLINE]

☐ **80:** Tack BF, Chapman PJ, Dagley S. Related Articles

Purification and properties of 4-hydroxy-4-methyl-2-oxoglutarate aldolase.
J Biol Chem. 1972 Oct 25;247(20):6444-9. No abstract available.
PMID: 5076765 [PubMed - indexed for MEDLINE]

☐ **81:** Tack BF, Chapman PJ, Dagley S. Related Articles

Metabolism of gallic acid and syringic acid by Pseudomonas putida.
J Biol Chem. 1972 Oct 25;247(20):6438-43. No abstract available.
PMID: 4342601 [PubMed - indexed for MEDLINE]

Display Summary Sort Save Text Clip Add Order
Show: 50 Items 51-81 of 81 Page 2 of 2 Select page: 1 2

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

WEST Search History

DATE: Tuesday, July 23, 2002

Set Name side by side	Query	Hit Count	Set Name result set
DB=EPAB,DWPI; PLUR=YES; OP=OR			
L7	L4	1	L7
L6	L5	0	L6
DB=DWPI; PLUR=YES; OP=OR			
L5	L1	0	L5
L4	Cathelicidin	1	L4
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L3	6040291[uref]	0	L3
L2	Cathelicidin	10	L2
L1	SMAP-29	2	L1

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. 20020090369 . 27 Jul 01. 11 Jul 02. Transplant media. Murphy, Chistopher J., et al. 424/94.63; 514/60 A61K038/48 A61K031/718.

☐ 2. 20020082195 . 19 Apr 01. 27 Jun 02. Novispirins: antimicrobial peptides. Lehrer, Robert I., et al. 514/2; 514/13 530/326 A61K038/16 A61K038/10 C07K007/04.

☐ 3. 20020072495 . 21 Sep 01. 13 Jun 02. LL-37 is an immunostimulant. Chertov, Oleg, et al. 514/12; A61K038/17.

☐ 4. 20020022668 . 21 May 01. 21 Feb 02. Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections. Welsh, Michael J., et al. 514/738; A61K031/045.

☐ 5. 20020009730 . 13 Feb 01. 24 Jan 02. Human stress array. Chenchik, Alex, et al. 435/6; 536/24.3 C12Q001/68 C07H021/04.

☐ 6. 6376248 . 16 Mar 98; 23 Apr 02. Peptide-enhanced transfections. Hawley-Nelson; Pamela, et al. 435/458; 435/235.1 435/320.1 536/23.1. C12N015/88 C12N007/00 C12N015/63 C12N015/11.

☐ 7. 6335318 . 10 May 99; 01 Jan 02. Antimicrobial theta defensins and methods of using same. Selsted; Michael E., et al. 514/13; 435/252.3 435/320.1 514/12 514/14 530/300 530/324 530/326 536/23.1. A61K038/00 C07K014/00 C07H021/02 C12N015/09.

☐ 8. 6172185 . 20 May 98; 09 Jan 01. Antimicrobial cationic peptide derivatives of bactenecin. Hancock; Robert E. W., et al. 530/326; 530/317 530/327. C07K007/08 A61K038/10.

☐ 9. 6040291 . 25 Mar 99; 21 Mar 00. Antimicrobial peptide. Hirata; Michimasa. 514/12; 210/690 210/908 514/13 525/54.1 530/324 530/326 530/810 536/127. A61K038/10 A61K038/16 B01D015/00 C07K007/08 C07K014/00.

☐ 10. AU 200189813 A, WO 200213857 A2 . Vaccine for active immunization or for preparing an adjuvant for enhancing an immune response to at least one antigen, comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide. BUSCHLE, M, et al. A61K039/39.

Generate Collection | Print

Terms	Documents
Cathelicidin	10

Previous Page Next Page

☐ Generate Collection

L2: Entry 8 of 10 File: USPT

DOCUMENT-IDENTIFIER: US 6172185 B1
TITLE: Antimicrobial cationic peptide derivatives of bactenecin

Other Reference Publication (1):
Storici P. et al., "Purification and structural character of bovine cathelicidins, precursors of antimicrobial peptides", European Journal of Biochemistry, vol. 238, No. 3, Jun. 15, 1996, pp. 769-776.

☐ Generate Collection

L2: Entry 9 of 10 File: USPT

US-PAT-NO: 6040291
DOCUMENT-IDENTIFIER: US 6040291 A

TITLE: Antimicrobial peptide

DATE-ISSUED: March 21, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hirata; Michimasa	Morioka			JP

US-CL-CURRENT: 514/12; 210/690, 210/908, 514/13, 525/54.1, 530/324, 530/326, 530/810, 536/127

CLAIMS:

What is claimed is:

1. An isolated peptide comprising at least the amino acid sequence of SEQ ID NO:1,

Wherein, the Xaa at amino acid 2 comprises a hydrophobic amino acid residue, the Xaa at amino acids 8, 12 and 16 comprise a hydrophilic amino acid residue, and the Xaa at amino acid 11 comprises an arbitrary amino acid residue.

2. The isolated peptide according to claim 1,

wherein said amino acid sequence is selected from the group consisting of; SEQ ID NOS:2-7.

3. An antimicrobial composition comprising the peptide as defined in claim 1 and a carrier.

4. An antimicrobial composition comprising the peptide as defined in claim 2 and a carrier.

5. A medicinal composition comprising the peptide as defined in claim 1 and a pharmaceutically acceptable carrier.

6. A medicinal composition comprising the peptide as defined in claim 2 and a pharmaceutically acceptable carrier.

7. A bacterial infection-treating composition comprising the peptide as defined in claim 1 and a pharmaceutically acceptable carrier.

8. A bacterial infection-treating composition comprising the peptide as defined in claim 2 and a pharmaceutically acceptable carrier.

9. An endotoxin shock-suppressing composition comprising the peptide as defined in claim 1 and a pharmaceutcally acceptable carrier.

10. An endotoxin shock-suppressing composition comprising the peptide as defined in claim 2 and a pharmaceutically acceptable carrier.

11. An endotoxin-removing agent comprising the peptide as defined in claim 1 immobilized to an insoluble carrier.

12. An endotoxin-removing agent comprising the peptide as defined in claim 2

immobilized to an insoluble carrier.

13. A method for treating bacterial infection, comprising administering to a living body in need of such treatment a therapeutically effective amount of the peptide as defined in claim 1.

14. A method for treating endotoxin shock, comprising administering to a living body in need of such treatment a therapeutically effective amount of the peptide as defined in claim 1.

15. A method for removing an endotoxin from a solution, comprising contacting a carrier to which the peptide as defined in claim 1 is immobilized, with a solution in which removal of the endotoxin is desired, to form a complex of the endotoxin in the solution and the peptide which is immobilized to the carrier, and separating the carrier from the solution.

16. A composition comprising the peptide as defined in claim 1 and a carrier.

☐ Generate Collection

L2: Entry 9 of 10 File: USPT

DOCUMENT-IDENTIFIER: US 6040291 A
TITLE: Antimicrobial peptide

Other Reference Publication (14):
Ole S.o slashed.rensen, et al., An Elisa for hCAP--18, the cathelicidin present in human neutrophils and plasma, Journal of Immunological Methods 206 (1997) pp. 53-59.

Other Reference Publication (15):
Ole S.o slashed.rensen, et al. The Human Antibacterial Cathelicidin, hCAP--, Is Synthesized in Myelocytes and Metamyelocytes and Localized to Specific Granules in Neutrophils, Blood, vol. 90 No. 7 (Oct. 1), 1997: pp. 2796-2803.

End of Result Set

☐ Generate Collection

L1: Entry 2 of 2 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020082195
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020082195 A1

TITLE: Novispirins: antimicrobial peptides

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lehrer, Robert I.	Santa Monica	CA	US	
Waring, Alan J.	Irvine	CA	US	
Tack, Brian F.	Iowa City	IA	US	

US-CL-CURRENT: 514/2; 514/13, 530/326

CLAIMS:

What is claimed is:

1. An antimicrobial polypeptide comprising the sequence, as set forth in SEQ ID NO:1, KNLRRX.sub.1X.sub.2RKX.sub.3X.sub.4HIIKKYG; wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of the D or L forms of glycine, threonione, serine and isoleucine, with the proviso that not more than 3 of the X residues are isoleucine.

2. The antimicrobial peptide of claim 1, wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of glycine, threonine, serine and, isoleucine, with the proviso that not more than 3 of the X residues are isoleucine.

3. The antimicrobial peptide of claim 2, wherein only one of X.sub.1, X.sub.2, X.sub.3 and X.sub.4 is selected from glycine, serine and threonine.

4. The antimicrobial peptide of claim 3, wherein said peptide comprises the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

5. The antimicrobial peptide of claim 4, wherein said peptide consists essentially of the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

6. The antimicrobial peptide of claim 1, wherein the carboxy terminus of said peptide is amidated.

7. An antimicrobial formulation, comprising: an antimicrobial polypeptide comprising the sequence, as set forth in SEQ ID NO:1, KNLRRX.sub.1X.sub.2RKX.sub.3X.sub.4HIIKKYG; wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of glycine, threonine, serine, glutamic acid, aspartic acid, isoleucine, D-alanine and D-isoleucine, with the proviso that not more than 3 of the X residues are isoleucine; and a pharmaceutically acceptable carrier.

8. The antimicrobial formulation of claim 7, wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of glycine, threonine, serine and, isoleucine, with the proviso that not more than 3 of the X residues are isoleucine.

9. The antimicrobial formulation of claim 8, wherein only one of X.sub.1, X.sub.2, X.sub.3 and X.sub.4 is selected from glycine, serine and threonine.

10. The antimicrobial formulation of claim 9, wherein said peptide comprises the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

11. The antimicrobial formulation of claim 10, wherein said peptide consists essentially of the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

12. The antimicrobial formulation of claim 7, wherein the carboxy terminus of the peptide is amidated.

13. The antimicrobial formulation of claim 7, wherein said pharmaceutically acceptable carrier comprises a chelating agent.

14. The antimicrobial formulation of claim 13, wherein said chelating agent is citrate.

15. The antimicrobial formulation of claim 7, further comprising a second antimicrobial agent.

16. The antimicrobial formulation of claim 15, wherein said second antimicrobial agent is an antibiotic.

17. The antimicrobial formulation of claim 7, wherein said formulation is suitable for aerosol delivery of said antimicrobial peptide.

18. A method for treating a microbial infection, the method comprising: contacting a microbial population with an antimicrobial polypeptide comprising the sequence, as set forth in SEQ ID NO:1, KNLRRX.sub.1X.sub.2RKX.sub.3X.sub.4HIIKKYG; wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of glycine, threonine, serine, glutamic acid, aspartic acid, isoleucine, D-alanine and D-isoleucine, with the proviso that not more than 3 of the X residues are isoleucine.

19. The method of claim 18, wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently selected from the group consisting of glycine, threonine, serine and, isoleucine, with the proviso that not more than 3 of the X residues are isoleucine.

20. The method of claim 19, wherein only one of X.sub.1, X.sub.2, X.sub.3 and X.sub.4 is selected from glycine, serine and threonine.

21. The method of claim 20, wherein said peptide comprises the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

22. The method of claim 21, wherein said peptide consists essentially of the amino acid sequence set forth in any one of SEQ ID NO:3 to SEQ ID NO:37.

23. The method of claim 18, wherein said microbial population comprises gram negative bacteria.

24. The method of claim 23, wherein said gram negative bacteria are one or more of Pseudomonas aeruginosa, Chalmydia trachomatis, Escherichia coli and Stenotrophomonas maltophilia.

25. The method of claim 18, wherein the carboxy terminus of the peptide is amidated.

26. The method of claim 18, wherein said peptide is formulated in a pharmaceutically acceptable carrier comprising a chelating agent.

27. The method of claim 26, wherein said chelating agent is citrate.